We are building AI-based solutions to solve the global cancer crisis
Our mission is to expand cancer screening and revolutionise cancer care by providing innovative, non-invasive, inexpensive AI-driven diagnostic solutions that enable early detection, personalised treatment monitoring and more effective patient management.
Screen.
We provide non-invasive, affordable and scalable methods to expand cancer screening globally.
Detect.
Profiling rare molecular events in the blood with high performing AI-based system deployable in low income countries.
Treat.
Many cancers are treatable if detected early. We provide a suite of data products that aid clinicians in their treatment decisions.
Monitor.
Our AI products allow for clinicians to detect and monitor drug resistance in order to predict and prevent relapse in multiple cancers.
Screen.
We provide non-invasive, affordable and scalable methods to expand cancer screening globally.
Detect.
Profiling rare molecular events in the blood with high performing AI-based system deployable in low income countries.
Treat.
Many cancers are treatable if detected early. We provide a suite of data products that aid clinicians in their treatment decisions.
Monitor.
Our AI products allow for clinicians to detect and monitor drug resistance in order to predict and prevent relapse in multiple cancers.
Screen.
We provide non-invasive, affordable and scalable methods to expand cancer screening globally.
Detect.
Profiling rare molecular events in the blood with high performing AI-based system deployable in low income countries.
Treat.
Many cancers are treatable if detected early. We provide a suite of data products that aid clinicians in their treatment decisions.
Monitor.
Our AI products allow for clinicians to detect and monitor drug resistance in order to predict and prevent relapse in multiple cancers.
Screen.
We provide non-invasive, affordable and scalable methods to expand cancer screening globally.
Detect.
Profiling rare molecular events in the blood with high performing AI-based system deployable in low income countries.
Treat.
Many cancers are treatable if detected early. We provide a suite of data products that aid clinicians in their treatment decisions.
Monitor.
Our AI products allow for clinicians to detect and monitor drug resistance in order to predict and prevent relapse in multiple cancers.
Our system outperforms
others in this space
We provide comprehensive patient insights for clinical partners with our diagnostic and theraputic dashboards.
Our system outperforms
others in this space
We provide comprehensive patient insights for clinical partners with our diagnostic and theraputic dashboards.
Our system outperforms
others in this space
We provide comprehensive patient insights for clinical partners with our diagnostic and theraputic dashboards.
Our system outperforms
others in this space
We provide comprehensive patient insights for clinical partners with our diagnostic and theraputic dashboards.
Clinical Trials
CCANED
CIPHER
The Common Cancer Early Detection study is phase 1 of our clinical trial, running from 2025 until 2027. The study will recruit 5,000 participants and investigate 7 common cancers. The study's aim is to gather data for the construction of our diagnostic dashboard, DiNanoQ, for early cancer detection.
KEY SCIENTISTS
Prof. Solomon Rotimi
Head of Research and Clinical Outreach
Dr. Javier Toledo
Chief Medical Officer
CCANED
CIPHER
The Common Cancer Early Detection study is phase 1 of our clinical trial, running from 2025 until 2027. The study will recruit 5,000 participants and investigate 7 common cancers. The study's aim is to gather data for the construction of our diagnostic dashboard, DiNanoQ, for early cancer detection.
KEY SCIENTISTS
Prof. Solomon Rotimi
Head of Research and Clinical Outreach
Dr. Javier Toledo
Chief Medical Officer
CCANED
CIPHER
The Common Cancer Early Detection study is phase 1 of our clinical trial, running from 2025 until 2027. The study will recruit 5,000 participants and investigate 7 common cancers. The study's aim is to gather data for the construction of our diagnostic dashboard, DiNanoQ, for early cancer detection.
KEY SCIENTISTS
Prof. Solomon Rotimi
Head of Research and Clinical Outreach
Dr. Javier Toledo
Chief Medical Officer
CCANED
CIPHER
The Common Cancer Early Detection study is phase 1 of our clinical trial, running from 2025 until 2027. The study will recruit 5,000 participants and investigate 7 common cancers. The study's aim is to gather data for the construction of our diagnostic dashboard, DiNanoQ, for early cancer detection.
KEY SCIENTISTS
Prof. Solomon Rotimi
Head of Research and Clinical Outreach
Dr. Javier Toledo
Chief Medical Officer
Technology
We are building the world’s largest platform for liquid biopsy omics data from exceptional responders, with the primary objective of transforming cancer treatment and advancing personalized medicine.
DiNanoTrack
DiNanoTrack is our treatment monitoring platform which aims to detect drug resistance and offer personalised solutions for treatment management, preventing further development or recurrence of cancer.
DiNanoQ
Our early cancer diagnostics test, DiNanoQ, is a non-invasive liquid biopsy test which will detect cancer and its origin. The Diagnostic Dashboard will track tests and results to individuals and clinics looking to take preventative measures.
DiNanoTrack
DiNanoTrack is our treatment monitoring platform which aims to detect drug resistance and offer personalised solutions for treatment management, preventing further development or recurrence of cancer.
DiNanoQ
Our early cancer diagnostics test, DiNanoQ, is a non-invasive liquid biopsy test which will detect cancer and its origin. The Diagnostic Dashboard will track tests and results to individuals and clinics looking to take preventative measures.
DiNanoTrack
DiNanoTrack is our treatment monitoring platform which aims to detect drug resistance and offer personalised solutions for treatment management, preventing further development or recurrence of cancer.
DiNanoQ
Our early cancer diagnostics test, DiNanoQ, is a non-invasive liquid biopsy test which will detect cancer and its origin. The Diagnostic Dashboard will track tests and results to individuals and clinics looking to take preventative measures.
DiNanoTrack
DiNanoTrack is our treatment monitoring platform which aims to detect drug resistance and offer personalised solutions for treatment management, preventing further development or recurrence of cancer.
DiNanoQ
Our early cancer diagnostics test, DiNanoQ, is a non-invasive liquid biopsy test which will detect cancer and its origin. The Diagnostic Dashboard will track tests and results to individuals and clinics looking to take preventative measures.
Screen. Detect. Treat. Monitor.
Join The Team
Dysplasia Diagnostics Limited © 2024.
Contact
info@dysplasiadx.co.uk
London, UK
85 Great Portland Street,
London, United Kingdom
W1W 7LT
San Francisco, USA
2261 Market Street STE
22954 San Francisco,
CA 94114
Screen. Detect. Treat. Monitor.
Join The Team
Dysplasia Diagnostics Limited © 2024.
Contact
info@dysplasiadx.co.uk
London, UK
85 Great Portland Street,
London, United Kingdom
W1W 7LT
San Francisco, USA
2261 Market Street STE
22954 San Francisco,
CA 94114
Screen. Detect. Treat. Monitor.
Join The Team
Dysplasia Diagnostics Limited © 2024.
Contact
info@dysplasiadx.co.uk
San Francisco, USA
2261 Market Street STE
22954 San Francisco,
CA 94114
London, UK
85 Great Portland Street,
London, United Kingdom
W1W 7LT
Screen. Detect. Treat. Monitor.
Join The Team
Dysplasia Diagnostics Limited © 2024.
Contact
info@dysplasiadx.co.uk
London, UK
85 Great Portland Street,
London, United Kingdom
W1W 7LT
San Francisco, USA
2261 Market Street STE
22954 San Francisco,
CA 94114